The end for QALYs in federal US drug value assessments?

Written by Joanne Walker
Decision science Editorials Health economics Market access Medical devices, pharmaceuticals and vaccines Value assessment

On February 7, 2024 the US House of Representatives passed new legislation banning the use of quality-adjusted life years (QALYs) in government healthcare programs, including Medicare and Medicaid. Here we discuss what this means for the QALY in the USA. The recent legislation banning the use of QALYs in federal healthcare programs, including Medicaid, has sparked intense debate and raised questions about the future of drug value assessments in the country. This move reflects a broader shift in healthcare policy toward ensuring that drug prices align with the value they bring to patients and society. First introduced in early 2023,...

To view this content, please register now for access

It's completely free